Search
IPH 1101
go.drugbank.com/drugs/DB05754ExperimentalIPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset.
PAC-113
go.drugbank.com/drugs/DB05756InvestigationalIt is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in saliva.
DNB-001
go.drugbank.com/drugs/DB05757InvestigationalDNB-001 is a first-in-class oral therapy with dual mechanism of action, which is initially being developed for the treatment of glaucoma.
Norclozapine
go.drugbank.com/drugs/DB05766InvestigationalACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia.
Alkaline Phosphatase
go.drugbank.com/drugs/DB05768InvestigationalAlkaline Phosphatase (AP) is an oral treatment and has a very favorable side-effect profile.
Arylacenamide
go.drugbank.com/drugs/DB05792ExperimentalIt is a dual agent with both immunomodulatory and antiproliferative activities. … Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2.
PRO-542
go.drugbank.com/drugs/DB05793InvestigationalPRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells. … PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates.
Daglutril
go.drugbank.com/drugs/DB05796InvestigationalDaglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.
ISIS 14803
go.drugbank.com/drugs/DB05803InvestigationalISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits
NS-2359
go.drugbank.com/drugs/DB05805InvestigationalNS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression. … Enhancing the function of the three neurotransmitters serotonin, noradrenalin and dopamine, NS2359 has a desired "triple-mode-of-action".